GlassScriptPhysician profile
Rama Shankar
NPI 1871590539
$1,768.07
in general payments reported to CMS, 2019-2025
17 companies · $289 in 2025
The $289 reported for 2025 was more than what 83% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $243 · 2023: $416 · 2024: $600 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $346.72 | 2021-2024 | Xarelto, Invega Sustenna |
| Pfizer INC. | $281.59 | 2021-2025 | |
| Abiomed | $191.80 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $180.62 | 2022-2024 | |
| Abbvie INC. | $175.76 | 2022-2025 | Dalvance |
| E.R. Squibb & Sons, L.L.C. | $121.97 | 2021-2025 | Eliquis, Camzyos |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.61 | 2024-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $56.38 | 2022-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $43.77 | 2025 | |
| Merck Sharp & Dohme LLC | $40.42 | 2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $35.77 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $35.14 | 2023-2024 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.59 | 2021-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $24.81 | 2024 | Terlivaz |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $20.90 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rama Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.